The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Azacitidine + quizartinib for patients with MDS and MPNs with FLT3 or CBL mutation
In this video, Tareq Abuasab, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the initial results of a Phase I/II study evaluating the use of azacitidine in combination with quizartinib for patients with myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs) with FLT3 or CBL mutation (NCT04493138). Dr Abuasab first comments on the patient population enrolled in this study and then highlights the exclusion criteria followed. To conclude, Dr Abuasab discusses some results from the dose-escalation part of this study, including the response rates observed and the efficacy of this combination. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
